Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes.

Chao BH, Lepeak L, Leal T, Robins HI.

Thrombosis. 2011;2011:530183. doi: 10.1155/2011/530183. Epub 2011 Apr 12.

2.

Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.

Bain E, Wilson A, Tooher R, Gates S, Davis LJ, Middleton P.

Cochrane Database Syst Rev. 2014 Feb 11;(2):CD001689. doi: 10.1002/14651858.CD001689.pub3. Review.

PMID:
24519568
3.

The heparins and cancer: review of clinical trials and biological properties.

Castelli R, Porro F, Tarsia P.

Vasc Med. 2004 May;9(3):205-13. Review.

PMID:
15675186
4.

International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Büller HR.

J Thromb Haemost. 2013 Jan;11(1):56-70. doi: 10.1111/jth.12070. Review.

6.

Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.

Andras A, Sala Tenna A, Crawford F.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD002001. doi: 10.1002/14651858.CD002001.pub2. Review.

PMID:
23076894
7.

Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J; American College of Chest Physicians..

Chest. 2008 Jun;133(6 Suppl):844S-886S. doi: 10.1378/chest.08-0761.

PMID:
18574280
8.

[Prophylaxis and treatment of venous thromboembolism in cancer patients. Clinical value of low-molecular-weight heparins].

Kreher S, Riess H.

Internist (Berl). 2014 Apr;55(4):448-54. doi: 10.1007/s00108-014-3476-z. German.

PMID:
24599489
9.

The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.

Gonda DD, Fridley J, Ryan SL, Briceño V, Lam SK, Luerssen TG, Jea A.

J Neurosurg Pediatr. 2015 Sep;16(3):329-34. doi: 10.3171/2015.1.PEDS14489. Epub 2015 Jun 12.

PMID:
26067336
10.

Anti-cancer properties of low-molecular-weight heparin: preclinical evidence.

Mousa SA, Petersen LJ.

Thromb Haemost. 2009 Aug;102(2):258-67. doi: 10.1160/TH08-12-0832. Review.

PMID:
19652876
11.

Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement.

Salazar CA, Malaga G, Malasquez G.

Cochrane Database Syst Rev. 2010 Apr 14;(4):CD005981. doi: 10.1002/14651858.CD005981.pub2. Review.

PMID:
20393944
12.

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

Di Nisio M, Porreca E, Otten HM, Rutjes AW.

Cochrane Database Syst Rev. 2014 Aug 29;(8):CD008500. doi: 10.1002/14651858.CD008500.pub3. Review. Update in: Cochrane Database Syst Rev. 2016 Dec 01;12 :CD008500.

PMID:
25171736
13.

Pharmacologic prophylaxis for venous thromboembolism and 30-day outcomes among older patients hospitalized with heart failure: an analysis from the ADHERE national registry linked to Medicare claims.

Kociol RD, Hammill BG, Hernandez AF, Klaskala W, Mills RM, Curtis LH, Fonarow GC.

Clin Cardiol. 2011 Nov;34(11):682-8. doi: 10.1002/clc.20986. Epub 2011 Nov 6.

14.

Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.

van Der Heijden JF, Hutten BA, Büller HR, Prins MH.

Cochrane Database Syst Rev. 2000;(4):CD002001. Review. Update in: Cochrane Database Syst Rev. 2002;(1):CD002001.

PMID:
11034739
15.

Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.

Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY.

J Thromb Haemost. 2009 May;7(5):760-5. doi: 10.1111/j.1538-7836.2009.03326.x. Epub 2009 Feb 24.

16.

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

Di Nisio M, Porreca E, Ferrante N, Otten HM, Cuccurullo F, Rutjes AW.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008500. doi: 10.1002/14651858.CD008500.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(8):CD008500.

PMID:
22336844
17.

[Treatment of venous thromboembolic disease in cancer patients].

Farge-Bancel D, Florea L, Bosquet L, Debourdeau P.

Pathol Biol (Paris). 2008 Jun;56(4):220-8. doi: 10.1016/j.patbio.2008.02.007. Epub 2008 Apr 3. Review. French.

PMID:
18394821
18.

Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients.

Junqueira DR, Perini E, Penholati RR, Carvalho MG.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD007557. doi: 10.1002/14651858.CD007557.pub2. Review.

PMID:
22972111
19.

Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.

Sobieraj DM, Coleman CI, Tongbram V, Chen W, Colby J, Lee S, Kluger J, Makanji S, Ashaye A, White CM.

Pharmacotherapy. 2012 Sep;32(9):799-808. doi: 10.1002/j.1875-9114.2012.01106.x. Epub 2012 Jun 28. Review.

PMID:
22744711
20.

Supplemental Content

Support Center